<DOC>
	<DOCNO>NCT01484262</DOCNO>
	<brief_summary>This study conduct Europe . The intention health service research study obtain data daily routine evaluate quality life cost disease patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Liraglutide Insulin Real Life Usage Patients With Diabetes Mellitus Type 2</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain studyrelated activity . ( Studyrelated activity procedure relate record data accord protocol ) Patients willing able give sign consent match patient data sick fund data Patients diagnose type 2 diabetes mellitus , currently treat oral antidiabetic medication , need treatment intensification insulin liraglutide ( VictozaÂ® ) due inadequate blood glucose control Patient member involve sick fund ( AOK Plus ) Known suspect contraindication relevant study product accord current SPC Previous participation study History type 1 diabetes mellitus Previous insulin treatment exclude emergency administration ( treatment duration maximum 3 day ) Previous treatment liraglutide History diabetic gastroparesis , diabetic precoma diabetic ketoacidosis Progressive fatal disease Any reason judgement treat physician precludes study participation e.g . lack compliance , safety concern , alcohol drug abuse Patients without legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>